JP-CSPC@EP2602A(17854.HK)

The Hang Seng Biotechnology Index rose over 4% intraday, CSPC PHARMA rose over 7%, INNOVENT BIO rose nearly 7%, WUXI BIO and SINO BIOPHARM rose over 5%

HSBC Research raises CSPC Pharma's revenue and earnings forecast, target price adjusted to HKD 11

HSBC's research report indicates that CSPC PHARMA has reached a $18.5 billion research and licensing cooperation agreement with AstraZeneca, which is expected to bring significant revenue growth. The bank has raised its revenue forecast for CSPC PHARMA for 2025 to 2027 by 3% to 11%, and its net profit forecast by 7% to 18%. HSBC maintains a "Buy" rating, raising the target price from 9 yuan to 11 yuan

Top 5 HK Stock Gainers/Losers (>100B) (2.3)

MINIMAX-WP(00100) rose 10.98%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 252.1%. KNOWLEDGE ATLAS(02513) rose 8.28%, with a trading turnover 616.0 Million HKD, and a year-to-date rose 109.3%. HTSC(06886) fell 8.24%, with a trading turnover 1.6 Billion HKD, and a year-to-date fell 10%. KUAISHOU-W(01024) fell 4.61%, with a trading turnover 5.1 Billion HKD, and a year-to-date rose 14.9%.

Huatai Securities Reaffirms Their Buy Rating on CSPC Pharmaceutical Group (CHJTF)

Huatai Securities has reaffirmed a Buy rating on CSPC Pharmaceutical Group (CHJTF), setting a price target of HK$19.25, while the stock closed at HK$9.15. The analyst consensus is a Moderate Buy with an average price target of HK$11.56, indicating a 26.33% upside. Additionally, CMB International Securities also maintains a Buy rating with a price target of HK$13.93.

The Hang Seng Index rose 54 points in the half-day session, tech stocks collectively plummeted, aerospace stocks surged, and Tencent dragged down 62 points | Hong Kong stock market midday

The Hang Seng Index opened 220 points higher this morning, but the gains narrowed later, with a minimum drop of 344 points. It ultimately closed at 26,830 points, up 54 points or 0.2%. The Tech Index reported 5,453 points at noon, down 72 points or 1.32%. CSPC PHARMA was approved to conduct clinical trials, with its stock price rising 4.15%. Internet stocks such as Kuaishou, Baidu, and Tencent fell by 4.35%, 3.54%, and 3.09% respectively. Commercial aerospace stocks rose collectively, with JunDa rising by as much as 12.95%. The three major U.S. stock indices rebounded, easing panic sentiment